Yuankai Shi

12PUBLICATIONS

25CO-AUTHORS

Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Computational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)Molecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jul 01, 2026

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

|Mar 26, 2026

Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma.

Zucheng Xie, Yan Qin, Xuemin Xue

|Apr 21, 2024

Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.

Zucheng Xie, Yan Qin, Xinrui Chen

|Oct 14, 2022

Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.

Xin Liu, Shiyu Jiang, Huijie Wang

|Feb 08, 2022

Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data.

Liling Huang, Shiyu Jiang, Yuankai Shi

|Jul 27, 2020

Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.

Haizhu Chen, Yan Qin, Jianliang Yang

Pageof 2

Frequent Collaborators

Liling Huang

Yuankai Shi

Xin Liu

Huijie Wang

Xianghua Wu

Wangjun Yan

Yong Chen

Yu Xu

Chunmeng Wang

Weiqiang Yao

Frequent Collaborators

Liling Huang

Yuankai Shi

Xin Liu

Huijie Wang